The decision by the US to choose Donald Trump as its President from January 2017 has already generated huge interest in what he plans to do on the domestic and geopolitical stage. TTIP and Brexit are likely to loom large on his agenda, and the effects will be felt in the pharmaceutical area, amongst others.
Brexit may have taken the world by surprise, but Donald Trump’s victory in the US presidential election has sent shock waves of a different order of magnitude across the globe.
Not only does this momentous event call into question many assumptions about the direction of US domestic and foreign policy,...
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
